Search Blog
Categories
October 2013
M T W T F S S
« Sep   Nov »
 123456
78910111213
14151617181920
21222324252627
28293031  

Tags

SODA, MACK, AEGR and NVAX added to NASDAQ Active Stock Watch List at EPR

admin

By Equity Profile Report

New York, NY – (ACCESSWIRE) – 10/30/2013 – Equity Profile Report initiates its NASDAQ Active Stock Weekly Watch List adding SodaStream International Ltd. (NASDAQ:SODA), Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), and Novavax, Inc. (NASDAQ:NVAX) 

SodaStream International Ltd. (NASDAQ:SODA) a company that engages in the development, manufacture, and sale of home beverage carbonation systems that enable consumers to transform ordinary tap water instantly into carbonated soft drinks and sparkling water is currently down (-7.00%) on 1,135,893 shares traded after SodaStream Reported Record Third Quarter Results. SodaStream International Ltd. (NASDAQ:SODA) is currently down (-24.16%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll. 

To find out what other Investors are saying about SodaStream International Ltd. (NASDAQ:SODA) 

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=SODA&SubId=AW 

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) a biopharmaceutical company that focuses on discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer in the United States is currently down (-21.01%) on 1,629,090 shares traded after Merrimack Pharmaceuticals Announced Results From A Phase 2 Study Of MM-121 SAR256212 In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is currently down (-63.07%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll. 

To find out what other Investors are saying about Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) 

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=MACK&SubId=AW 

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) a biopharmaceutical company that engages in the development and commercialization of novel therapeutics to treat debilitating and fatal rare diseases in the United States is currently up (+1.84%) on 456,922 shares traded after Aegerion Pharmaceuticals Announced Third-Quarter 2013 Financial Results. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) is currently up (+429.63%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll. 

To find out what other Investors are saying about Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) 

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=AEGR&SubId=AW 

Novavax, Inc. (NASDAQ:NVAX) a clinical-stage biopharmaceutical company that focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases is current up (+4.84%) on 760,486 shares traded after coverage was initiated on Novavax by FBR Capital. Novavax, Inc. (NASDAQ:NVAX) is currently up (+101.97%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll. 

To find out what other Investors are saying about Novavax, Inc. (NASDAQ:NVAX) 

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=NVAX&SubId=AW 

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.equityprofilereport.com/

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures. 

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com